Exclusion criteria:
|
1. Those who do not meet the inclusion criteria;
2. Patients with specific liver diseases such as alcoholic liver disease (ALD), viral hepatitis, autoimmune liver disease, hepatolenticular degeneration, etc., can lead to fatty liver;
3. Medications (such as tamoxifen, amiodarone, sodium valproate, methotrexate, glucocorticoids, etc.), total parenteral nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome, etc β Fatty liver caused by lipoprotein deficiency and some syndromes related to insulin resistance (lipoatrophic diabetes, Mauriac syndrome);
4. Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, and hematopoietic systems, malignant tumors, other serious comorbidities, or mental illness;
5. The patient has diabetes or is receiving anti diabetes drugs; 6. Patients who are using NAFLD treatment drugs (including Chinese herbal decoction, traditional Chinese patent medicines and simple preparations and chemical drugs) and ALT ≥ 5 times the standard value;
7. Known allergies to the components of the research product or patients with allergic constitution;
8. Pregnant and lactating women, as well as women who refuse to maintain the contraceptive measures recognized by the researchers throughout the entire study process and are at risk of pregnancy;
9. Those who have participated in other clinical trials in the past three months or are currently participating in other clinical trials;
10. Those who are unable to follow medical advice for therapeutic lifestyle changes;
11. Suspect having a history of drug abuse or having other patients who do not meet the inclusion criteria.
|